Louisiana Product Liability Lawyer for GLP-1 RA Litigation

GLP-1 RAs are a class of medications commonly used to treat conditions like type 2 diabetes and obesity by mimicking a natural hormone that regulates blood sugar and appetite. However, despite their benefits, these drugs can be dangerous, carrying an increased risk of severe side effects that can significantly impact a person’s health and well-being.

At The Greenwald Law Firm, we understand the challenges faced by individuals who have suffered from severe side effects associated with weight loss drugs, including popular medications like Ozempic and Mounjaro. That’s why our law firm is dedicated to holding pharmaceutical companies accountable for their actions, ensuring that patients who were inadequately warned about the potential dangers of these drugs receive the justice they deserve.

If you or a loved one has been adversely affected by GLP-1 RAs, experienced Shreveport products liability lawyer Joey Greenwald is here to help. To speak with a member of our legal team regarding your potential case, call (318) 219-7867 or reach out online today!

GLP-1 RA Lawsuit

What is GLP-1 RA?

GLP-1 RA, or glucagon-like peptide-1 receptor agonists, are prescription drugs approved to treat diabetes and provide chronic weight management, among other uses. These receptor agonist drugs mimic the natural hormone GLP-1 to regulate appetite and blood sugar levels. Originally intended for the treatment of type 2 diabetes, clinical trials found that they are also able to treat obesity by significantly decreasing a patient’s appetite.  

However, there are growing concerns about the safety and potential adverse side effects of GLP-1 RAs. The long-term impact and safety profile of these receptor agonist drugs remain subjects of intense debate and scrutiny.

Is Ozempic a GLP-1?

Yes, the prescription drug Ozempic is a GLP-1 receptor agonist used primarily to treat diabetes. It falls under a class of diabetes therapy drugs designed to improve blood sugar control by mimicking the effects of the GLP-1 hormone, which helps regulate insulin levels in the body. 

Due to its effects on weight and blood sugar, it has become a popular treatment option, both for patients with diabetes and those without. As with many medications, however, there are potential side effects and legal concerns associated with the drug, which has led to lawsuits being filed against Novo Nordisk, Ozempic’s manufacturer. 

If you have taken Ozempic, experienced adverse side effects, and would like to participate in Ozempic litigation, it’s important that you seek the assistance of a skilled Ozempic lawyer like Joseph Greenwald, Jr. to address these complications legally.

What is GLP-1 RA

What are GLP-1 RA Medications?

Although GLP-1 receptor agonists are mostly intended to be diabetes drugs, they are now being used not just for managing blood sugar but also for treating obesity and aiding in long-term weight management. 

Below, we’ll cover common GLP-1 RA drugs such as Ozempic, Wegovy, Mounjaro, and similar drugs that are becoming increasingly widespread and, as a result, leading to a large number of patients experiencing dangerous side effects.


The diabetes drug Ozempic is one of the most commonly prescribed and heavily used GLP-1 receptor agonists on the market. Ozempic is administered through subcutaneous injection, meaning it is injected under the skin, typically in the abdomen, thigh, or upper arm. It comes in a pre-filled, disposable, single-use pen that is generally used once a week.

Ozempic has gained massive popularity for its effectiveness in managing blood sugar levels and assisting with weight loss, and while many individuals taking Ozempic have experienced significant health improvements, there are a large number who have experienced adverse reactions linked to the drug. 

If you or someone you love has taken Ozempic and suffered health complications as a result, call a Louisiana Ozempic lawyer at Greenwald Law Firm today to learn more about your legal options.


Wegovy is another GLP-1 receptor agonist drug that, like Ozempic, is manufactured by Novo Nordisk. It is also administered via injection. Designed primarily for the treatment of obesity, Wegovy helps patients manage their weight more effectively by regulating appetite and calorie intake. 

This medication is specifically targeted at individuals needing medical assistance to achieve significant long-term weight loss.


Yet another GLP-1 RA drug manufactured by Novo Nordisk is called Rybelsus. Rybelsus is aimed at improving blood sugar control in adults with type 2 diabetes. 

However, unlike other GLP-1 RA drugs that require injection, Rybelsus is notable for being the first in its class to be available in an oral tablet form, making it a convenient option for diabetes patients looking to manage their condition with less invasive treatment methods.


Mounjaro is a GLP-1 receptor agonist drug developed by Eli Lilly and Company. Like Ozempic and Rybelsus, it is designed to enhance blood sugar control in adults with type 2 diabetes. 

However, what makes Mounjaro unique is that it not only acts as a GLP-1 receptor agonist but also targets the GIP receptor, making it a dual-action treatment.


Trulicity is another GLP-1 receptor agonist drug manufactured by Eli Lilly and Company. It is specifically designed to help improve blood sugar levels in adults with type 2 diabetes. 

Administered through once-weekly injections, Trulicity is intended to aid in glycemic control by enhancing the body’s natural ability to release insulin in response to increased blood sugar levels.

Glucagon-like Peptide-1 Receptor Agonists

Risks of Glucagon-like Peptide-1 Receptor Agonists

If something seems too good to be true, it probably is. While proving very effective for blood sugar and weight management, Glucagon-like peptide-1 receptor agonists are unfortunately also associated with several risks and potential adverse effects, ranging from acid reflux to serious gastrointestinal injuries. 

Here are some of the alleged dangers linked to the use of these drugs:

  • Abdominal pain
  • Severe gastrointestinal issues, including nausea, vomiting, diarrhea, and constipation
  • Stomach paralysis (gastroparesis)
  • Pancreatitis
  • Kidney failure
  • Hypoglycemia
  • Cyclic vomiting syndrome
  • Bowel obstruction
  • Injection site reactions
  • Gallbladder issues
  • Thyroid tumors
  • And more

While GLP-1 RAs offer significant benefits in managing conditions like type 2 diabetes and obesity, the potential for serious side effects requires careful consideration and monitoring by healthcare professionals. Patients are advised to discuss the full range of possible risks with their doctor to make an informed decision about their treatment options.

Why Are People Suing Novo Nordisk and Eli Lilly?

People are suing Novo Nordisk and Eli Lilly and Company due to legal issues surrounding their GLP-1 receptor agonist drugs, with plaintiffs bringing forth substantially similar allegations against both drug manufacturers. These lawsuits claim that the companies failed to adequately warn consumers about the potentially severe side effects and health complications associated with their drugs.

In these cases, plaintiffs allege that both Novo Nordisk and Eli Lilly did not provide sufficient information on the risks of their medications, leading to unexpected and sometimes severe adverse health outcomes.

Class Action Lawsuit for GLP-1 RAs

Is There a Class Action Lawsuit for GLP-1 RAs?

Currently, there is no Ozempic class action lawsuit in progress, nor is there a class action lawsuit for other GLP-1 receptor agonists (RAs). 

However, this does not mean you cannot file an Ozempic lawsuit. While there is no class action at the moment, there is a nationwide multi-district litigation lawsuit involving GLP-1 RAs.

Class Action vs. Multi-District Litigation

Wherein a class action lawsuit, a single lawsuit is filed on behalf of a group of people who have suffered similar harm or injuries, multi-district litigation (MDL) involves the consolidation of multiple civil cases that share common questions of fact and involve similar defendants, but where the individual circumstances of each case may differ.

Multidistrict Litigation 3094

MDL 3094 refers to a multi-district litigation case consolidated in the Eastern District of Pennsylvania Federal Court against drug manufacturers Novo Nordisk (Ozempic, Wegovy, and Rybelsus) and Eli Lilly and Company (Trulicity and Mounjaro). 

This legal action is under the oversight of the United States Judicial Panel on Multidistrict Litigation, which determined that centralizing the cases would promote the just and efficient conduct of the litigation. 

In these personal injury actions, the core issue revolves around whether the defendants adequately warned plaintiffs about the potential risks associated with their products. More specifically, the lawsuit alleges that the defendants:

  • Knew or should have known that their products can cause gastroparesis and other gastrointestinal injuries;
  • Did not adequately warn plaintiffs or their prescribing physicians about the alleged dangers of these products; or
  • Made false, misleading, or incomplete representations regarding the safety of these products.
Multidistrict Litigation 3094

How To Join MLD 3094

If you’ve experienced adverse effects from using Ozempic, Wegovy, Rybelsus, Trulicity, or Mounjaro, particularly if these effects relate to undisclosed risks associated with these medications, you might want to consider joining MDL 3094

To do this, you should start by equipping yourself with an attorney who has experience handling mass tort litigation and pharmaceutical lawsuits. Your attorney can evaluate your case to determine if it fits the criteria of MDL 3094. This can be done by gathering medical records, documentation of the weight-related condition treated with these drugs, and any evidence of the side effects suffered. 

If the case is deemed suitable, your attorney will file a claim on your behalf, which would then be transferred to the Eastern District of Pennsylvania Federal Court where MDL 3094 is centralized. This process allows for coordinated pretrial proceedings, including discovery and any potential settlement discussions, ensuring efficient handling of the case alongside others with similar allegations.

How Shreveport Products Liability Attorney Joey Greenwald Can Help

When it comes to products liability litigation, including Ozempic lawsuits and similar cases, Shreveport attorney Joey Greenwald is well-versed in helping clients throughout the entire legal process to secure fair compensation for both economic and non-economic losses, as well as punitive damages where applicable. 

Attorney Greenwald’s experience in product liability cases ensures that all legal avenues are explored to demonstrate the full extent of harm caused by defective or dangerous products. Whether it involves negotiating with large corporations or representing clients in MDL cases, Joey Greenwald is committed to advocating for the rights of those injured by faulty products and dangerous drugs.

Louisiana GLP-1 RA Attorney

Seeking Compensation for GLP-1 RA-Related Injuries? Call The Greenwald Law Firm Today

If you have experienced adverse effects from using Ozempic, Wegovy, Mounjaro, or other GLP-1 RA weight loss drugs, it’s crucial to seek legal advice ASAP to understand your rights and options.

Our experienced Ozempic attorneys at The Greenwald Law Firm in Shreveport, Louisiana, are here to evaluate your situation and guide you through the process to seek the compensation you deserve.

Contact our Shreveport personal injury attorneys at The Greenwald Law Firm today by calling (318) 219-7867 or complete our online intake form to schedule a free consultation and learn more about how we can help you on your path to justice.

Call Now Button